147 What are the main concerns of participants in a drug trial for chronic breathlessness?

• DOI: 10.1136/bmjspcare-2019-asp.170
• Publication Date: 2020-05-08T03:27:27Z
• Authors: S Singh; N Lovell; D Yi; IJ Higginson
• Keywords: 16. Peace & justice; 3. Good health

<h3>Background</h3> Chronic breathlessness is a common, distressing advanced illness symptom. Previous work has synthesised patient concerns, but not specifically within trial setting. <h3>Aims</h3> To determine the main concerns of participants in drug for chronic and assess change during trial. <h3>Methods</h3> Data was collected as part multi-centre randomised placebo controlled, double-blind feasibility Mirtazapine patients with (ISRCTN 33236160). The question 'What have been your or problems over past 3 days?' Integrated Palliative Outcomes Scale (IPOS) asked at three time-points (baseline, day 14, 28). Participants were able to provide up answers. A free text analysis done, categorised using domains total breathlessness. Results compared across change. <h3>Results</h3> 64 participated 73% male; median age 72 years (range 51–90). 63% had diagnosis obstructive pulmonary disease, 30% interstitial lung 8% heart failure cancer. 267 responses collected. most commonly reported (n=46 baseline, n=20 n=28 28), fatigue (n=7 n=6 28) mobility (n=4 n=7 n=4 Using model breathlessness, 81% physical domain. 23% psychological, 6% spiritual, 3% social. 35/267 showed overlap multiple <h3>Conclusion</h3> Physical common. Concerns appeared remain stable period. It crucial that outcome measures which reflect are selected.